Skip to content

Analysis of Specimens From Individuals With Pulmonary Fibrosis

Analysis of Specimens From Individuals With Pulmonary Fibrosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00084305
Enrollment
315
Registered
2004-06-10
Start date
2004-06-09
Completion date
Unknown
Last updated
2026-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers, Hermansky-Pudlak Syndrome (HPS), Pulmonary Fibrosis

Keywords

Bronchoscopy, Pulmonary Fibrosis, Lung Biopsy (Clinically-Indicated), Natural History

Brief summary

The etiology of pulmonary fibrosis is unknown. Analyses of blood, genomic DNA, and specimens procured by bronchoscopy, lung biopsy, lung transplantation, clinically-indicated extra-pulmonary biopsies, or post-mortem examination from individuals with this disorder may contribute to our understanding of the pathogenic mechanisms of pulmonary fibrosis. The purpose of this protocol is to procure and analyze blood, genomic DNA, and specimens by bronchoscopy, lung biopsy, lung transplantation, extra-pulmonary biopsies, or post-mortem examination from subjects with pulmonary fibrosis. In addition, blood, genomic DNA, clinically-indicated extra-pulmonary biopsies, as well as bronchoscopy and post-mortem examination specimens may be procured and analyzed from relatives of subjects with hereditary forms of pulmonary fibrosis; blood, genomic DNA, and bronchoscopy specimens may be procured from healthy research volunteers.

Detailed description

The etiology of pulmonary fibrosis is unknown. Analyses of blood, genomic DNA, and specimens procured by bronchoscopy, lung biopsy, lung transplantation, clinically-indicated extra-pulmonary biopsies, or post-mortem examination from individuals with this disorder may contribute to our understanding of the pathogenic mechanisms of pulmonary fibrosis. The purpose of this protocol is to procure and analyze blood, genomic DNA, and specimens by bronchoscopy, lung biopsy, lung transplantation, extra-pulmonary biopsies, or post-mortem examination from subjects with pulmonary fibrosis. In addition, blood, genomic DNA, clinically-indicated extra-pulmonary biopsies, as well as bronchoscopy and post-mortem examination specimens may be procured and analyzed from relatives of subjects with hereditary forms of pulmonary fibrosis; blood, genomic DNA, and bronchoscopy specimens may be procured from healthy research volunteers.

Interventions

None listed

Sponsors

National Human Genome Research Institute (NHGRI)
Lead SponsorNIH

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 115 Years
Healthy volunteers
No

Inclusion criteria

* INCLUSION CRITERIA: Individuals who are 18 years of age or older with any of the following: * Idiopathic pulmonary fibrosis \[defined by the American Thoracic Society/European Respiratory Society guidelines\], * Familial pulmonary fibrosis \[defined as idiopathic pulmonary fibrosis in two or more first-degree relatives\], * Relatives of patients with hereditary pulmonary fibrosis, * Hermansky-Pudlak syndrome (diagnosed by paucity or deficiency of platelet dense bodies on whole mount electron microscopy or by genetic testing), * Pulmonary fibrosis associated with collagen vascular diseases or autoinflammatory disorders, * Pulmonary fibrosis post-COVID-19 \[i.e., pulmonary fibrosis in an individual recovering from SARS-CoV-2 infection\], or * Healthy research volunteers by history and indicated tests (individuals without history of chronic pulmonary disorder, collagen vascular disease, or bleeding disorder).

Exclusion criteria

Individuals with any of the following: * Significant inhalational exposure to fibrogenic fibers or dusts or exposure to drugs associated with pulmonary fibrosis, * Uncontrolled ischemic heart disease, * Uncorrectable bleeding diathesis, * Pregnancy or lactation (excluded due to exposure of unnecessary risks), or * Inability to give informed consent (excluded due to exposure of unnecessary risks).

Design outcomes

Primary

MeasureTime frameDescription
Procure and analyzeOngoingThe objectives and specific aims of this protocol are to procure and analyze blood and cell/tissue specimens from individuals with pulmonary fibrosis, relatives of subjects with familial pulmonary fibrosis, and healthy research volunteers.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORWendy J Introne, M.D.

National Human Genome Research Institute (NHGRI)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 17, 2026